Coronary disease & ACS

Impact of baseline risk of death or hospitalization on effectiveness of revascularization in patients with ischaemic left ventricular dysfunction—a prespecified analysis of REVIVED-BCIS2

Eur Heart J Qual Care Clin OutcomesPublished Secondary analysis of the REVIVED-BCIS2 randomised trial

Authors' conclusion

Baseline risk did not influence the effect of revascularization in preventing all-cause mortality or hospitalization due to heart failure. A trend was observed that lower baseline risk might be associated with more benefit of revascularization in preventing cardiovascular death or hospitalization due to heart failure.

Study context

Population
Patients with ischaemic cardiomyopathy263 (37.6%) had primary outcome
Participants
700 patients
Comparison
Percutaneous coronary intervention (PCI) plus optimal medical therapy (OMT) vs OMT alone, by baseline risk
Primary endpoint
All-cause mortality or HF hospitalisation
Follow-up
Median 41 months
Methodological detailsprespecified analysis
  • Prespecified analysis

Primary result

As reported in the abstract

Modification of PCI effect on primary outcome by baseline risk score
No statistical evidence that baseline risk score modified the trial intervention effect
pinteraction = 0.21

Secondary outcomes

Prediction model performance (12 predictors)

C statistic
0.69 (95% CI 0.66-0.72)
Calibration slope
0.79 (95% CI 0.64-0.95)

CV death or hospitalization due to HF, modification by baseline risk

Weak evidence baseline risk modified the trial intervention effect; lower risk trended towards greater benefit from PCI
P for interaction = 0.044

Original publication

Impact of baseline risk of death or hospitalization on effectiveness of revascularization in patients with ischaemic left ventricular dysfunction—a prespecified analysis of REVIVED-BCIS2. Eur Heart J Qual Care Clin Outcomes. Published 16 September 2025. doi:10.1093/ehjqcco/qcaf108

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.